"I love NuProbe | Improving analytical sensitivity in DNA biomarkers"

2022-10-01 09:01:09

Close Search TechnologyBlocker Displacement Amplification (BDA)BDA Technology OverviewBDA Research AssaysQuantitative Amplicon Sequencing (QASeq)QASeq Technology OverviewQASeq Research AssaysServicesAugury™ Biopharma ServicesPublicationsCompanyAboutNewsEventsCareersContact Us Pioneering Precision Diagnostics NuProbe applies breakthrough technologies in genomics research to enable diseases to be detected, treated, and cured at early stages for better outcomes with lower costs. NuProbe Closes $50M in New Fundraising Upcoming Presentation –AMP Annual Meeting New Publication –QASeq: Simultaneous Ultrasensitive Detection of CNVs and Mutations from FFPE Tissue and cfDNA New Publication –Algorithm for Designing Highly Multiplex PCR Primer Sets. Read More New Publication –Simultaneous enrichment and identification of multiple mutations below 0.1% VAF using qPCR. Read More Technology Blocker DisplacementAmplificationRare allele enrichment technology by PCR that enables the selective amplification and detection of low-abundant sequence variants down to 0.01% variant allele frequency (VAF). Quantitative AmpliconSequencingNGS-based method that utilizes unique molecular identifiers (UMIs) and highly multiplexed partially nested PCR primer design to detect mutations and copy number variations with high sensitivity. Accelerating Precision Oncology Worldwide Clinical and Research LaboratoriesAt NuProbe, we are developing innovative assays to accelerate cancer research. Our products allow laboratories to detect and quantify low-abundant variants across multiple platforms from both cell-free DNA and tissue specimens. Contact us today to learn more. PharmaWe provide assay development and testing services to support all stages of biomarker detection programs. Our flexible platform utilizes proprietary technologies to deliver best-in-class sensitivity from solid tumor and liquid biopsy. Contact one of our experts today to find out what NuProbe can do for you. Contact Us Never miss an updateStay in touch for the latest NuProbe developmentsSubscribe News & Press Releases Jun 02 2022 Love0 NuProbe Closes $50M in New Fundraising By Danielle Kraus All News, Company News, Strategic Collaborations Houston, TX, Jun 02, 2022 — NuProbe Global, a genomics and molecular diagnostics company, announces the close of its $50M…Read More Apr 19 2022 Love0 NuProbe Published Method for Designing Highly Multiplex PCR Primer Sets By Danielle Kraus All News, Technology SADDLE approach uses computational primer design to minimize primer-dimer formation, and thus does not require enzymatic primers and primer-dimer removal.Read More Apr 05 2022 Love0 NuProbe QASeq Technology Enables Simultaneous Ultrasensitive Detection of CNVs and Mutations from FFPE Tissue and cfDNA By Danielle Kraus All News, Technology The results show detection of CNVs down to 5% heterozygous single copy gain or loss, and mutations down to 0.1% variant allele frequency (VAF), from both formalin-fixed, paraffin-embedded (FFPE) tissue samples and from cell-free DNA (cfDNA) samples1.Read More Click here for more news Upcoming EventsNOV 01-05, 2022AMP Annual MeetingDEC 10-13, 2022ASH Annual MeetingJAN 25-27, 2023Precision Medicine World Conference For Research Use Only. Not for use in diagnostic procedures.[email protected]+1 713-485-0148USA2575 West Bellfort Avenue,Ste. 200Houston, TX 77054China489 Zhengli Rd,Yangpu DistrictShanghai, ChinaCompanyTechnologyAboutNewsEventsCareersContactPublications © 2022 NuProbe. All Rights Reserved. This website uses cookies. By continuing to use this site, you accept our use of cookies. View our Privacy Policy Close MenuTechnologyBlocker Displacement Amplification (BDA)BDA Technology OverviewBDA Research AssaysQuantitative Amplicon Sequencing (QASeq)QASeq Technology OverviewQASeq Research AssaysServicesAugury™ Biopharma ServicesPublicationsCompanyAboutNewsEventsCareersContact Us X